Intent to Sole Source Good Manufacturing Practices (GMP) Influenza A Primer Kits
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases Influenza Division (NCIRD/ID), intends to award a sole source, firm fixed price purchase order to Biosearch Technologies Inc. for Good Manufacturing Practices (GMP) Influenza A Primer Kits. This acquisition aims to secure specifically designed oligonucleotide reagents of GMP quality level for influenza genomic surveillance. Capability statements from interested firms are due by February 9, 2026, at 5:00 p.m. ET.
Scope of Work
The requirement is for GMP Influenza A Primer Kits, which are oligonucleotide reagents manufactured to 21 CFR 820 quality standards. These kits are essential for the CDC's Influenza Division to monitor and investigate influenza viruses. They support genomic surveillance by enabling the amplification of all eight gene segments of Influenza A viruses using a one-step multi-segment reverse transcription polymerase chain reaction (M-RTPCR) method.
Contract & Timeline
- Type: Intent to Sole Source, Firm Fixed Price Purchase Order
- Target Vendor: Biosearch Technologies Inc., Petaluma, CA
- NAICS Code: 325413, In-Virtro Diagnostic Substance Manufacturing
- Product Service Code: 6550, In Vitro Diagnostic Substances, Reagents, Test Kits And Sets
- Response Due: February 9, 2026, 5:00 p.m. ET
- Published: January 26, 2026
Response Information
This notice indicates an intent to award non-competitively to Biosearch Technologies Inc. No competitive solicitation will be posted. However, firms that believe they can meet this requirement are encouraged to submit a written capability statement to the contract specialist, Dawnnia Daley (xwf5@cdc.gov). The government's decision not to proceed with a sole source award will be based on responses received and is at the contracting officer's discretion. Information submitted will be used solely to determine if a competitive procurement is feasible.